📊 MAJI Key Takeaways
Is Exousia Pro, Inc. (MAJI) a Good Investment?
Nextel Medical is in severe financial distress with zero revenue, negative stockholders' equity of -$463.3K, and minimal assets of $1.0K against liabilities of $464.3K. The company is technically insolvent with negative operating cash flow and no discernible business operations, representing an extreme risk of total loss.
Exousia Pro, Inc. shows no operating business traction, with zero reported revenue, persistent operating and net losses, and negative free cash flow in the latest filing. Financial health is extremely weak given no cash, a near-empty asset base, and deeply negative equity, while the underlying data is also stale as of July 31, 2020, which adds uncertainty rather than improving the fundamental case.
Why Buy Exousia Pro, Inc. Stock? MAJI Key Strengths
- No strengths identified
- Absolute loss and cash burn are small in dollar terms
- No meaningful capital expenditure burden was reported
- Liability base is modest in absolute size despite severe balance sheet weakness
MAJI Stock Risks: Exousia Pro, Inc. Investment Risks
- Zero revenue and no operational business activity
- Negative stockholders' equity indicating technical insolvency
- Liabilities exceed assets by $463.3K with minimal cash runway
- Negative operating cash flow of -$61.3K with no ability to fund operations
- Negligible asset base of $1.0K provides no liquidation value protection
- Data is stale as of July 31, 2020 with no recent insider activity indicating abandonment
- No reported revenue indicates no proven operating business or commercialization
- Negative stockholders equity and zero cash point to severe financial distress
- Stale SEC financial data from 2020 reduces visibility into current operations and solvency
Key Metrics to Watch
- Return to positive revenue or business activity
- Debt restructuring or capital injection
- Total asset value trend
- Revenue generation and gross profit emergence
- Cash balance and stockholders equity improvement
Exousia Pro, Inc. (MAJI) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
MAJI Profit Margin, ROE & Profitability Analysis
MAJI vs Telecom Sector: How Exousia Pro, Inc. Compares
How Exousia Pro, Inc. compares to Telecom sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Exousia Pro, Inc. Stock Overvalued? MAJI Valuation Analysis 2026
Based on fundamental analysis, Exousia Pro, Inc. has mixed fundamental signals relative to the Telecom sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Exousia Pro, Inc. Balance Sheet: MAJI Debt, Cash & Liquidity
MAJI Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Exousia Pro, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline.
MAJI Revenue Growth, EPS Growth & YoY Performance
MAJI Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2021 | N/A | $5.6K | N/A |
| Q3 2020 | N/A | $5.6K | N/A |
| Q2 2020 | N/A | $5.6K | N/A |
| Q1 2020 | N/A | $5.6K | N/A |
| Q3 2019 | N/A | -$36 | N/A |
| Q2 2019 | N/A | -$36 | N/A |
| Q3 2012 | N/A | -$19.9K | N/A |
| Q2 2012 | N/A | -$28.1K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Exousia Pro, Inc. Dividends, Buybacks & Capital Allocation
MAJI SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Exousia Pro, Inc. (CIK: 0001492448)
📋 Recent SEC Filings
❓ Frequently Asked Questions about MAJI
What is the AI rating for MAJI?
Exousia Pro, Inc. (MAJI) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 94% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are MAJI's key strengths?
Claude: . ChatGPT: Absolute loss and cash burn are small in dollar terms. No meaningful capital expenditure burden was reported.
What are the risks of investing in MAJI?
Claude: Zero revenue and no operational business activity. Negative stockholders' equity indicating technical insolvency. ChatGPT: No reported revenue indicates no proven operating business or commercialization. Negative stockholders equity and zero cash point to severe financial distress.
What is MAJI's revenue and growth?
Exousia Pro, Inc. reported revenue of $0.0.
Does MAJI pay dividends?
Exousia Pro, Inc. does not currently pay dividends.
Where can I find MAJI SEC filings?
Official SEC filings for Exousia Pro, Inc. (CIK: 0001492448) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is MAJI's EPS?
Exousia Pro, Inc. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is MAJI a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Exousia Pro, Inc. has a STRONG SELL rating with 94% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is MAJI stock overvalued or undervalued?
Valuation metrics for MAJI: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 14%). Compare these metrics with sector averages to assess valuation.
Should I buy MAJI stock in 2026?
Our dual AI analysis gives Exousia Pro, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is MAJI's free cash flow?
Exousia Pro, Inc.'s operating cash flow is $-61.3K, with capital expenditures of N/A.
How does MAJI compare to other Telecom stocks?
Vs Telecom sector averages: Net margin N/A (avg: 14%), ROE N/A (avg: 15%), current ratio 0.00 (avg: 1).